Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• TanguturADKumarDKrishnaKVKantevariSMicrotubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilising and destabilising agentsCurr Top Med Chem Epub201714
   PubMedGoogle Scholar
• WijdevenRHPangBAssarafYGNeefjesJOld drugs, novel ways out: drug resistance toward cytotoxic chemotherapeuticsDrug Resist Updat201628658127620955
   PubMed Web of Science ®Google Scholar
• WallsGMLyonARHarbinsonMTHannaGGCardiotoxicity following cancer treatmentUlster Med J20178613928298705
   PubMedGoogle Scholar
• PapadasAAsimakopoulosFMechanisms of resistance in multiple myelomaHandb Exp Pharmacol Epub2017318
   Google Scholar
• ColmegnaBMorosiLD’IncalciMMolecular and pharmacological mechanisms of drug resistance: an evolving paradigmHandb Exp Pharmacol Epub2017323
   Google Scholar
• ZhouZTangMLiuYZhangZLuRLuJApigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell lineAnticancer Drugs201728444645628125432
   PubMed Web of Science ®Google Scholar
• ChenMWangXZhaDApigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent mannerSci Rep201663546827752089
   PubMed Web of Science ®Google Scholar
• LeeYMLeeGOhTIInhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stressInt J Oncol201648139940826573871
   PubMed Web of Science ®Google Scholar
• ChengCYHuCCYangHJLeeMCKaoESInhibitory effects of scutellarein on proliferation of human lung cancer A549 cells through ERK and NFκB mediated by the EGFR pathwayChin J Physiol201457418218725246059
   PubMed Web of Science ®Google Scholar
• ZhangJLiuDHuangYGaoYQianSBiopharmaceutics classification and intestinal absorption study of apigeninInt J Pharm20124361–231131722796171
   PubMedGoogle Scholar
• CastoldiAHerrCNiederstraßerJCalcifediol-loaded liposomes for local treatment of pulmonary bacterial infectionsEur J Pharm Biopharm Epub20161122
   PubMed Web of Science ®Google Scholar
• JøraholmenMWBasnetPAcharyaGŠkalko-BasnetNPEGylated liposomes for topical vaginal therapy improve delivery of interferon alphaEur J Pharm Biopharm201711313213928087379
   PubMed Web of Science ®Google Scholar
• FouladiFSteffenKJMallikSEnzyme-responsive liposomes for the delivery of anticancer drugsBioconjug Chem201728485786828201868
   PubMed Web of Science ®Google Scholar
• LeeYThompsonDHStimuli-responsive liposomes for drug deliveryWiley Interdiscip Rev Nanomed Nanobiotechnol Epub2017215
   Web of Science ®Google Scholar
• PanahiYFarshbafMMohammadhosseiniMRecent advances on liposomal nanoparticles: synthesis, characterization and biomedical applicationsArtif Cells Nanomed Biotechnol201745478878928278586
   PubMed Web of Science ®Google Scholar
• ChangHIYehMKClinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyInt J Nanomedicine20127496022275822
   PubMed Web of Science ®Google Scholar
• BozzutoGMolinariALiposomes as nanomedical devicesInt J Nanomedicine20151097599925678787
   PubMed Web of Science ®Google Scholar
• DuhemNDanhierFPréatVVitamin E-based nanomedicines for anti-cancer drug deliveryJ Control Release2014182334424631865
   PubMed Web of Science ®Google Scholar
• GuoYLuoJTanSOtienoBOZhangZThe applications of Vitamin E TPGS in drug deliveryEur J Pharm Sci201349217518623485439
   PubMed Web of Science ®Google Scholar
• ZhangZTanSFengSSVitamin E TPGS as a molecular biomaterial for drug deliveryBiomaterials201233194889490622498300
   PubMed Web of Science ®Google Scholar
• ShenRKimJJYaoMElbayoumiTADevelopment and evaluation of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceuticalInt J Nanomedicine2016111687170027217747
   PubMed Web of Science ®Google Scholar
• HaoJTongTJinKFolic acid-functionalized drug delivery platform of resveratrol based on Pluronic 127/D-α-tocopheryl polyethylene glycol 1000 succinate mixed micellesInt J Nanomedicine2017122279229228392687
   PubMed Web of Science ®Google Scholar
• ZhangXYZhangPYCombinations in multimodality treatments and clinical outcomes during cancerOncol Lett20161264301430428101195
   PubMed Web of Science ®Google Scholar
• Bhaw-LuximonAJhurryDArtemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectivesCancer Chemother Pharmacol201779345146628210763
   PubMed Web of Science ®Google Scholar
• CosenzaMCivalleroMPozziSMarcheselliLBariASacchiSThe combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell linesHematol Oncol2015334166175
   PubMed Web of Science ®Google Scholar
• ArasBYerlikayaABortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3Oncol Lett20161153179318427123085
   PubMed Web of Science ®Google Scholar
• HuangYTZhaoLFuZTherapeutic effects of tyroservatide on metastasis of lung cancer and its mechanism affecting integrin-focal adhesion kinase signal transductionDrug Des Devel Ther201610649663
   PubMed Web of Science ®Google Scholar
• XuQLuRZhuZFEffects of tyroservatide on histone acetylation in lung carcinoma cellsInt J Cancer2011128246047220309941
   PubMed Web of Science ®Google Scholar
• FuZLuRJiaJInhibition of five xenografted human cancers and two murine cancers by the tripeptide tyroservatideAnticancer Drugs200718446747017351399
   PubMed Web of Science ®Google Scholar
• ZhengMLuRCheXTyroservatide therapy for tumor growth, invasion and metastasis of Lewis lung carcinoma and human lung carcinoma A549Oncology200670641842617245103
   PubMed Web of Science ®Google Scholar
• JinXLiMYinLZhouJZhangZLvHTyroservatide-TPGS-paclitaxel liposomes: tyroservatide as a targeting ligand for improving breast cancer treatmentNanomedicine20171331105111527845234
   PubMed Web of Science ®Google Scholar
• JinXZhangYZhangZCheDLvHJuglone loaded poloxamer 188/phospholipid mixed micelles evaluated in vitro and in vivo in breast cancerInt J Pharm20165151–235936627744033
   PubMedGoogle Scholar
• TaurinSNehoffHGreishKAnticancer nanomedicine and tumor vascular permeability; Where is the missing link?J Control Release2012164326527522800576
   PubMed Web of Science ®Google Scholar
• ChouTCDrug combination studies and their synergy quantification using the Chou-Talalay methodCancer Res201070244044620068163
   PubMed Web of Science ®Google Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev200658362168116968952
   PubMed Web of Science ®Google Scholar
• ChenMZhangYChenZXieSLuoXLiXSynergistic antitumor efficacy of redox and pH dually responsive micelleplexes for co-delivery of camptothecin and genesActa Biomater20174944445527940163
   PubMed Web of Science ®Google Scholar